{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:38:57Z","timestamp":1780461537268,"version":"3.54.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40744-025-00765-7","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T08:16:03Z","timestamp":1746778563000},"page":"627-639","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of Ixekizumab in Chinese Patients with Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Level"],"prefix":"10.1007","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct04285229","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ning","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiankang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongzhou","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaxiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Lie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyu","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cibo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hejian","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"issue":"12","key":"765_CR1","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1136\/annrheumdis-2021-221035","volume":"80","author":"V Navarro-Comp\u00e1n","year":"2021","unstructured":"Navarro-Comp\u00e1n V, Sepriano A, El-Zorkany B, van der Heijde D. Axial spondyloarthritis. Ann Rheum Dis. 2021;80(12):1511\u201321.","journal-title":"Ann Rheum Dis"},{"issue":"10089","key":"765_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73\u201384.","journal-title":"Lancet"},{"issue":"8","key":"765_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s11926-022-01079-1","volume":"24","author":"S Zhang","year":"2022","unstructured":"Zhang S, Peng L, Li Q, Zhao J, Xu D, Zhao J, et al. Spectrum of spondyloarthritis among Chinese populations. Curr Rheumatol Rep. 2022;24(8):247\u201358.","journal-title":"Curr Rheumatol Rep"},{"issue":"7","key":"765_CR4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/RHU.0000000000000589","volume":"23","author":"V Strand","year":"2017","unstructured":"Strand V, Singh JA. Patient burden of axial spondyloarthritis. J Clin Rheumatol. 2017;23(7):383\u201391.","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"765_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19\u201334.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"765_CR6","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/acr.24025","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2019;71(10):1285\u201399.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"765_CR7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1136\/ard-2022-223298","volume":"82","author":"C Webers","year":"2023","unstructured":"Webers C, Ortolan A, Sepriano A, Falzon L, Baraliakos X, Landew\u00e9 RBM, et al. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Ann Rheum Dis. 2023;82(1):130\u201341.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"765_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2014-000017","volume":"1","author":"JR Maneiro","year":"2015","unstructured":"Maneiro JR, Souto A, Salgado E, Mera A, Gomez-Reino JJ. Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. RMD Open. 2015;1(1): e000017.","journal-title":"RMD Open"},{"issue":"6","key":"765_CR9","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.semarthrit.2018.10.019","volume":"48","author":"X Baraliakos","year":"2019","unstructured":"Baraliakos X, Szumski A, Koenig AS, Jones H. The role of C-reactive protein as a predictor of treatment response in patients with ankylosing spondylitis. Semin Arthritis Rheum. 2019;48(6):997\u20131004.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"765_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.2312","volume":"5","author":"R Wang","year":"2022","unstructured":"Wang R, Dasgupta A, Ward MM. Predicting probability of response to tumor necrosis factor inhibitors for individual patients with ankylosing spondylitis. JAMA Netw Open. 2022;5(3): e222312.","journal-title":"JAMA Netw Open"},{"issue":"10163","key":"765_CR11","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16-week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441\u201351.","journal-title":"Lancet"},{"issue":"4","key":"765_CR12","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/art.40753","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol. 2019;71(4):599\u2013611.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"765_CR13","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","volume":"79","author":"M Dougados","year":"2020","unstructured":"Dougados M, Wei JC, Landew\u00e9 R, Sieper J, Baraliakos X, Van den Bosch F, et al. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis. 2020;79(2):176\u201385.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"765_CR14","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1093\/rheumatology\/keac104","volume":"61","author":"WP Maksymowych","year":"2022","unstructured":"Maksymowych WP, Bolce R, Gallo G, Seem E, Geneus VJ, Sandoval DM, et al. Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging. Rheumatology (Oxford). 2022;61(11):4324\u201334.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"765_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40259-023-00625-2","volume":"38","author":"Y Xue","year":"2024","unstructured":"Xue Y, Hu J, Liu D, Li J, Wu H, Tan C, et al. Ixekizumab for active radiographic axial spondyloarthritis in Chinese patients: 16- and 52-week results from a phase III, randomized, double-blind, placebo-controlled study. BioDrugs. 2024;38(1):145\u201356.","journal-title":"BioDrugs"},{"key":"765_CR16","doi-asserted-by":"crossref","unstructured":"Sengupta R. Machado PM, Goupille P, Navarro Comp\u00e1n V, Huji X, Sheesh M, Jing Ng K, Ngantcha M, Russ H, Doridot G, Baraliakos X. Baseline Characteristics and Efficacy in Patients with Radiographic AxSpA (r-axSpA) Stratified by CRP Level: An Analysis from the Ixekizumab Phase III Trial [abstract]. Arthritis Rheumatol. 2024;76(suppl 9). Available from: https:\/\/acrabstracts.org\/abstract\/baseline-characteristics-and-efficacy-in-patients-with-radiographic-axspa-r-axspa-stratified-by-crp-level-an-analysis-from-the-ixekizumab-phase-iii-trial\/. Accessed Dec 2024.","DOI":"10.1016\/j.ard.2025.06.060"},{"issue":"12","key":"765_CR17","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1136\/ard.2008.100826","volume":"68","author":"D van der Heijde","year":"2009","unstructured":"van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(12):1811\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"765_CR18","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286\u201391.","journal-title":"J Rheumatol"},{"issue":"2","key":"765_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000749","volume":"4","author":"J Braun","year":"2018","unstructured":"Braun J, Deodhar A, Landew\u00e9 R, Baraliakos X, Miceli-Richard C, Sieper J, et al. Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies. RMD Open. 2018;4(2): e000749.","journal-title":"RMD Open"},{"key":"765_CR20","doi-asserted-by":"crossref","unstructured":"Reveille J RP, Sandoval D, Muran T, Kronbergs A, Bolce R, Geneus V, Hunter T, Liu-Leage S, Rudwaleit M, Maldonado-Cocco J, Van den Bosch F. Response to Ixekizumab by C-reactive protein level in patients with radiographic axial spondyloarthritis: results from the COAST-V (biological-na\u00efve) and COAST-W (TNF inhibitor-experienced) trials at 52 weeks. In: Poster presented at the American College of Rheumatology convergence, November 5\u20139, 2020 (all virtual); abstract 0904. Available from: https:\/\/acrabstracts.org\/abstract\/response-to-ixekizumab-by-c-reactive-protein-level-in-patients-with-radiographic-axial-spondyloarthritis-results-from-the-coast-v-biological-naive-and-coast-w-tnf-inhibitor-experienced-trials-at\/. Accessed Dec 2024.","DOI":"10.1093\/rheumatology\/keab247.189"},{"issue":"3","key":"765_CR21","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s40744-024-00660-7","volume":"11","author":"K de Vlam","year":"2024","unstructured":"de Vlam K, Maksymowych WP, Gallo G, Rahman P, Mease P, Krishnan V, et al. Exploring the effects of ixekizumab on pain in patients with ankylosing spondylitis based on objective measures of inflammation: post hoc analysis from a large randomized clinical trial. Rheumatol Ther. 2024;11(3):691\u2013707.","journal-title":"Rheumatol Ther"},{"key":"765_CR22","doi-asserted-by":"crossref","unstructured":"Zhu X, Hu J, Liu D, Li J, Wu H, Sun L, et al. Rapid and sustained effect of ixekizumab on patient global, spinal pain, stiffness, and fatigue in Chinese patients with radiographic axial spondyloarthritis. Rheumatol Ther. 2024;11(4):1011\u201322.","DOI":"10.1007\/s40744-024-00688-9"},{"key":"765_CR23","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3389\/fimmu.2019.00305","volume":"10","author":"WP Maksymowych","year":"2019","unstructured":"Maksymowych WP. Biomarkers for diagnosis of axial spondyloarthritis, disease activity, prognosis, and prediction of response to therapy. Front Immunol. 2019;10:305.","journal-title":"Front Immunol"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00765-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00765-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00765-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T15:28:05Z","timestamp":1757172485000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00765-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["765"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00765-7","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"assertion":[{"value":"19 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yan Yan and Hongying Li are employees of Eli Lilly and Company. Ning Kong, Jiankang Hu, Dongzhou Liu, Jingyang Li, Huaxiang Wu, Lingyun Sun, Dai Lie, Chunyu Tan, Zhijun Li, Zhengyu Xiao, Cibo Huang, Jian Xu, and Hejian Zou have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol was approved by local ethics committees (Supplementary Table ) and the study was conducted in accordance with the principles outlined in the Declaration of Helsinki and the Council of International Organizations of Medical Sciences International Ethical Guidelines. All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}